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Introduction: B lymphocytes might play a pathogenic role in dermal fibrosis in systemic sclerosis (SSc). B-cell
activating factor (BAFF), a key cytokine for B-cell activation, is increased in the serum and the skin of patients with
SSc. However, the ability of B cells directly to stimulate dermal fibroblasts and the role of BAFF are not fully
understood. We therefore investigated the involvement of B cells and BAFF in the expression of collagen and
profibrotic markers by dermal fibroblasts.
Methods: Cocultures of blood B cells from healthy blood donors and normal or SSc dermal fibroblasts stimulated
with anti-IgM and BAFF were performed. Alpha-SMA, TIMP1, MMP9, COL1A1, COL1A2, and COL3A1 mRNA expression
were determined by quantitative RT-PCR. Soluble collagen, BAFF, IL-6, IL-1β, TGF-β1, and CCL2 protein secretion
were assessed.
Results: Coculture of blood B cells and dermal fibroblasts isolated from SSc patients induced IL-6, TGF-β1, CCL2,
and collagen secretion, as well as Alpha-SMA, TIMP1, and MMP9 expression in dermal fibroblasts. Transwell assays
demonstrated that this induction was dependent on cell-cell contact. Addition of anti-IgM and BAFF to the coculture
increased IL-6, CCL2, TGF-β1, and collagen secretion. B cell- and BAFF-induced collagen secretion was highly reduced
by anti-TGF-β1 antibodies.
Conclusions: Our results showed for the first time a direct role of B cells on the production of collagen by dermal
fibroblasts, which is further enhanced by BAFF. Thus, these results demonstrate a new pathogenic role of B cells and
BAFF in fibrosis and systemic sclerosis.Introduction
Systemic sclerosis (SSc) is a systemic autoimmune dis-
ease that has a complex pathogenesis involving genetic
and environmental factors [1,2]. SSc is characterized by
vascular hyperreactivity, skin and visceral organs fibrosis,
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reproduction in any medium, provided the orautoantibodies [3]. Fibrosis results from excessive colla-
gen production by fibroblasts, and recent studies uncov-
ered that B cells might play a role in the development of
fibrosis. It was demonstrated that B cell-deficient mice
treated with CC14 to trigger hepatic fibrosis showed a
reduced collagen deposition by a mechanism dependent
on antibodies but independent of T cells [4]. Likewise,
CD19-deficient mice exhibit a reduced susceptibility to
pulmonary fibrosis after bleomycin challenge, whereas
CD19 overexpression exacerbates fibrosis [5]. SSc patients
also have B-cells abnormalities such as the production of
specific autoantibodies. Moreover, the presence of CD20+
B cells and immunoglobulin genes were detected in skinl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and TGF-β1, which have been shown to regulate col-
lagen synthesis by fibroblasts [8]. In SSc patients, IL-6
serum levels correlate with skin fibrosis, and IL-6-
deficient mice have attenuated collagen deposition in
lungs after bleomycin challenge [9,10]. TGF-β1 also has
the ability to inhibit collagen degradation by decreasing
matrix metalloproteinases (MMPs) and increasing tissue
inhibitor of metalloproteinases (TIMPs) expression [11].
Survival of peripheral B cells is crucially dependent on B
cell-activating factor (BAFF) and a proliferation-inducing
ligand (APRIL) [12]. The finding that BAFF-transgenic
mice develop autoimmune manifestations with similarities
to systemic lupus erythematosus and Sjögren syndrome in
humans suggested a critical role of BAFF in autoimmune
diseases [13,14]. Elevated levels of BAFF have been detected
in serum and skin samples from patients with SSc, which
suggests that this cytokine contributes to B-cell abnormal-
ities and disease development in patients with SSc [15,16].
The pathogenic role of B cells and BAFF in SSc might
not be restricted to secretion of immunoglobulins, antigen
presentation, or cytokine secretion. However, to date, no
study addressed the ability of B cells to stimulate fibro-
blasts directly. To investigate the involvement of B cells in
dermal fibrosis, we used a coculture model of human der-
mal fibroblasts (HDFs) isolated from healthy controls or
SSc patients with blood B cells and assessed collagen and
profibrotic cytokine and markers expression. The present
study demonstrates that B cells and BAFF are capable of
stimulating collagen secretion by dermal fibroblasts.
Methods
Patients and cells
Primary cultures of human dermal fibroblasts (HDFs)
were established by outgrowth of cells from explanted tis-
sue pieces. Skin biopsies were obtained by punch biopsies
from three healthy subjects (NHDF) and from six patients
with SSc (SScHDF) of the Departement de Rhumatologie,
Hôpitaux Universitaires de Strasbourg, France. Blood
mononuclear cells were isolated from six healthy blood do-
nors. Approval by the ethical committee of the Hopitaux
Universitaires de Strasbourg was obtained. Informed
consent was obtained from patients and healthy donors.
Diagnosis of SSc was performed according to the re-
vised criteria of the American College of Rheumatology
(ACR). All patients were female and had diffuse cutane-
ous systemic sclerosis and anti-Scl70-positive antibodies.
All biopsies were isolated from the forearm of SSc pa-
tients. The modified Rodnan skin scores were 29, 8, 0,
25, 28, and 14, respectively. Two patients were treated
with oral prednisone (Cortancyl) (5 or 10 mg/day, respect-
ively), and one patient was treated with methotrexate
(10 mg/week). Three patients were treated with both oral
prednisone and methotrexate. HDFs were used in theexperiments between the third and the sixth passages.
Blood mononuclear cells were isolated from healthy blood
donors by Ficoll-Paque centrifugation, as described in
standard protocols. B cells were then selected by negative
sorting by using EasySep Human B Cell Enrichment Kit
(Stemcell Technologies Grenoble, France). The efficacy of
B-cell isolation was determined with FACS analysis by
using anti-CD19 antibodies. The yield of isolated B cells
was composed of 99% CD19+/CD3- B cells, 0.01% of
CD19-/CD3+ T cells, and 0.09% of CD19-/CD3- cells.
Cultures and reagents
Cells were cultured in RPMI1640 supplemented with fetal
calf serum (FCS), penicillin, streptomycin, amphotericin B
(all from Invitrogen). HDF (105 cells) alone, B cells (3 × 105
or 5 × 105 cells) alone, or cocultures were seeded in 24-well
plates for 3 or 5 days. For transwell experiments, B cells
(5 × 105 cells) and HDF (105 cells) were seeded in the upper
and lower chambers, respectively, of a 0.4-μm polycar-
bonate membrane transwell (Nunc Dominique Dutscher,
Brumath, France). For fibroblasts stimulation, cells were in-
cubated with 5 ng/ml of recombinant TGF-β1 (from R&D
Systems Lille, France). For B-cell stimulation, cells were
incubated with 100 ng/ml of soluble recombinant human
BAFF (rhBAFF; R&D systems Lille, France) in the presence
of 5 μg/ml goat F(ab′)2 anti-human μ-chain Ab (Jackson
ImmunoResearch Laboratories Suffolk, UK) [17]. Anti-
LAP-TGF-β1 (AF-246-NA), anti-IL-6 (Clone 6708), anti-
integrin α4/VLA4/CD49d (Very Late Antigen-4, Clone
2B4), or control IgG (all from R&D Systems Lille, France)
were incubated at 20 μg/ml, unless specified in the figure
legends.
Real-time quantitative RT-PCR
Total RNA was extracted from cells by using the phenol/
chloroform separation method, as described in standard
protocols (Trizol; Invitrogen Fischer Scientific, Illkirch,
France) and then reverse-transcribed by using iScript
cDNA Synthesis Kit (BioRad Marnes-la-Coquette, France).
Real-time quantitative PCR was performed in a total vol-
ume of 20 μl by using SensiMix Plus SYBR kit (Quantace;
Corbett Life Science Qiagen, Courtaboeuf, France). After
an initial incubation at 95°C for 10 minutes, samples were
subjected to 40 rounds of amplification for 15 seconds at
95°C, 15 seconds at 60°C, and 25 seconds at 72°C by using
a Rotor-Gene 6000 real-time PCR machine (Qiagen
Courtaboeuf, France). Melting-curve analysis was per-
formed to assess the specificity of PCR products. The fold
of a specific gene was calculated according to the equation
fold ¼ 2‐ ΔCt2‐ΔCt1ð Þ;
in which ΔCt (change in cycle threshold) is the cycle
threshold of the test gene minus the cycle threshold of
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sample. The primers used are GAPDH forward (5′- GG
TGAAGGTCGGAGTCAACGGA-3′) and reverse (5′-GA
GGGATCTCGCTCCTGGAAGA-3′); COL1A1 forward
(5′-CACACGTCTCGGTCATGGTA-3′) and reverse (5′-CG
GCTCCTGCTCCTCTTAG-3′); COL1A2 forward (5′-AGC
AGGTCCTTGGAAACCTT-3′) and reverse (5′-GAAAAG
GAGTTGGACTTGGC-3′); COL3A1 forward (5′-ATATT
TGGCATGGTTCTGGC-3′) and reverse (5′-TGGCTACT
TCTCGCTCT GCT-3′); ACTA2 (α-SMA) forward (5′-GA
TGGCCACTGCCGCATCCT-3′) and reverse (5′-ACAGGG
TCTCTGGGCAGCGG-3′); MMP9 forward (5′-TTGGTC
CACCTGGTTCAACT-3′) and reverse (5′-ACGACGTCTT
CCAGTACCGA-3′); TIMP1 forward (5′-TTGACTTCTG
GTGTCCCCAC-3′) and reverse (5′-CTGTTGTTGCTGT
GGCTGAT-3′); BAFF-R (TNFRSF13C) forward (5′-GAT
TCCCGGAGACAGAATGA-3′) and reverse (5′-GTGGGTC
TGGTGAGCTGG-3′); TACI (TNFRSF13B) forward (5′-AT
CCCAGTACTGCTCTTCGG-3′) and reverse (5′-CTGAG
TAATGAGTGGCCTGG-3′); BCMA (TNFRSF17) forward
(5′-CAG TCCTGCTCTTTTCCAGG-3′) and reverse (5′-
TGGCAGTTTTCGTGCTAATG-3′).Enzyme-linked immunosorbent assay
Human BAFF, IL-6, CCL2 (MCP-1), latent and active
TGF-β1, and IL-1β were assessed in 3- and 5-day culture
supernatants by using a standard ELISA kit according to
the manufacturer’s instructions (R&D Systems Lille,
France).Collagen measurements in cell-culture supernatants
Aliquots of supernatant (200 μl) were assayed for colla-
gen levels and compared with a standard curve prepared
from bovine skin by using the Sircol collagen dye-
binding assay, according to the manufacturer’s instruc-
tions (Biocolor Ltd. Interchim, Montluçon, France).NHDF SS
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Figure 1 B cells upregulate collagen secretion by dermal fibroblasts.
collagen dye-binding assay in 3-day culture supernatants of NHDF or SScH
PBMC (light gray bars), or recombinant TGF-β1 (5 ng/ml, dark gray bars). Data
experiments with B cells or PBMCs isolated from controls, NHDF from three d
SSc ± interquartile range. NS, not significant; ***P < 0.001.B-cell viability assay
B cells alone or cocultured with fibroblasts were seeded in
24-well plates for 3 or 5 days. For transwell experiments,
B cells (5 × 105 cells) and HDF (105 cells) were seeded in
the upper and lower chambers, respectively, of a 0.4-μm
polycarbonate membrane transwell (Nunc). After 3 or
5 days, B cells were stained with 3,3-dihexyloxacarbocya-
nine iodide (DiOC6) to assess the mitochondrial trans-
membrane potential (Ψm), and with propidium iodide
(PI) to assess membrane permeability. In brief, cell sus-
pensions were incubated with 40 nM DiOC6 and 1 μg/ml
PI for 15 minutes at 37°C, washed with FACS buffer, and
then analyzed on FACS Calibur (BD Biosciences Le Pont
de Claix, France). A lymphocyte gate was set by using
forward-angle and side-angle light-scatter characteristics
of lymphocytes. The vital B cells were brightly positive
when stained with DiOC6 and excluded PI.Statistical analysis
Values were reported as the median ± interquartile range.
Two-tailed Mann–Whitney test was used to compare two
independent groups by using GraphPad software. A prob-
ability (P) value of <0.05 was considered to be significant.Results
B cells induce the production of collagen by dermal
fibroblasts from SSc patients and healthy controls
To study the role of B cells in the induction of collagen
synthesis, dermal fibroblasts isolated from patients with
SSc (SScHDF) or healthy individuals (NHDF) were cocul-
tured with purified blood B cells isolated from healthy con-
trols. Only 1% of B cells cultured alone were alive at day 5,
whereas 49% were alive after coculture with fibroblasts (see
Additional file 1: Figure S1). As shown in Figure 1, 5.105 B
cells strongly induced collagen secretion by 105 NHDF and
SScHDF (black bars), with a magnitude comparable to thatcHDF
Fibroblast alone
Fibroblast + B cells
Fibroblast + PBMC
Fibroblast + TGF-
Collagen release by dermal fibroblasts was determined by the Sircol
DF cultured alone (white bars), cocultured with B cells (black bars), with
are expressed as the median of duplicate samples from independent
ifferent healthy individuals, and SScHDF from six different patients with
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Figure 2 Expression of collagen and profibrotic markers is
increased in SScHDF cocultured with B cells. (A) Levels of
COL1A1, COL1A2, and COL3A1 mRNA were determined with RT-qPCR
in SScHDF cocultured with blood B cells (black bars) for 3 days.
Results were normalized to GAPDH and were expressed as the fold
change compared with samples from SScHDF alone (white bars).
(B) Collagen release by SScHDF was determined by the Sircol collagen
dye-binding assay in 3- and 5-day culture supernatants. (C) Levels of
α-SMA, MMP9, and TIMP1 mRNA were determined with RT-qPCR in the
same conditions as panel A. Data are expressed as the median of
duplicate samples of six independent experiments ± interquartile
range. *P < 0.05; **P < 0.01; ***P < 0.001.
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bars). To confirm that the stimulating effect of B cells was
not related to the B cell/fibroblast ratio, additional experi-
ments using 3 × 105 B cells or 5 × 105 B cells were per-
formed and showed that a lower ratio of B cells/fibroblasts
was still effective to induce collagen secretion (data not
shown). However, no difference was observed between
SScHDF or NHDF. Then, to determine whether the induc-
tion of collagen in dermal fibroblasts is specific to B cells,
we also cocultured dermal fibroblasts with PBMCs. We
observed that the levels of collagen in the supernatants
were not affected by the presence of PBMCs compared
with dermal fibroblasts cultured alone.
Coculture of B cells and SScHDFs induces the expression
of collagen and profibrotic markers
To study the role of B cells in the expression of collagen
and profibrotic markers by SScHDF, we first evaluated
mRNA levels of COL1A1, COL1A2, and COL3A1, which
encode type I and type III collagens in SScHDF. As shown
in Figure 2A, coculture of SScHDF with B cells for 3 days
significantly induced the expression of COL1A1, COL1A2,
and COL3A1. Moreover, levels of collagen released in the
supernatant were significantly higher compared with
SScHDF alone after 3 and 5 days of coculture (Figure 2B).
Then, we assessed the expression of profibrotic markers
with SScHDF. The differentiation of fibroblasts into con-
tractile myofibroblasts expressing α-smooth muscle actin
(α-SMA) amplifies the pathologic reparative process in sys-
temic sclerosis. Interestingly, levels of α-SMA mRNA were
significantly increased in SScHDF when they were cocul-
tured with B cells (Figure 2C). Levels of TIMP1, also im-
plicated in tissue remodeling, evolved in a comparable
manner to α-SMA levels (Figure 2C). Levels of MMP9,
known to be increased and well correlated with skin scores
in systemic sclerosis [18], were considerably increased in
SScHDF cocultured with B cells (Figure 2C). These find-
ings suggest that B cells promote collagen secretion and α-
SMA,TIMP1, and MMP9 expression by dermal fibroblasts.
BAFF upregulates the expression of collagen, α-SMA,
and TIMP1 in SScHDF cocultured with B cells
We first determined the level of BAFF in the super-
natant of cultured cells. BAFF could not be detected in
the supernatant of fibroblasts alone, B cells alone and in
the cocultures (data not shown). Because levels of BAFF,
secreted mainly by myeloid cells, are importantly in-
creased in SSc, we investigated whether BAFF could
amplify collagen secretion. Cocultured B cells and fibro-
blasts were incubated with anti-human μ-chain anti-
bodies, to mimic B cell-receptor engagement, alone or
concomitant with soluble BAFF [17]. BAFF did not have
any effect on collagen production by SScHDF cultured
alone (Figure 3A,B), and no expression by fibroblasts of
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Figure 3 B cell-induced collagen secretion and profibrotic markers expression are contact dependent, and the role of BAFF is
dependent on soluble factors. (A) Levels of COL1A1, COL1A2, and COL3A1 mRNA were determined with RT-qPCR in SScHDF after incubation
with medium (white bars), anti-μ-chain antibodies at 5 μg/ml (grey bars), or anti-μ and rhBAFF at 100 ng/ml (black bars) in the presence or
absence of blood B cells. B cells were either in contact with SScHDF (contact) or seeded in the upper chamber of a transwell culture insert
(transwell). Results were expressed as the fold change compared with samples from SScHDF alone with medium. (B) Collagen release by SScHDF
was determined by the Sircol collagen dye-binding assay in 3 and 5 days of culture supernatants. (C) Levels of α-SMA, MMP9, and TIMP1 mRNA
were determined with RT-qPCR in the same conditions as in panel A. Data are expressed as the median of duplicate samples of six independent
experiments ± interquartile range. *P < 0.05; **P < 0.01.
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http://arthritis-research.com/content/15/5/R168BCMA, BAFF-R, and TACI could be detected by using
qPCR (data not shown). After 3 days of coculture, the
addition of BAFF significantly upregulated COL1A1,
COL1A2, and COL3A1 mRNA levels in SScHDF
(Figure 3A). Moreover, a significant upregulation incollagen secretion was detected after 5 days of co-
culture (Figure 3B). In addition, levels of α-SMA and
TIMP1, but not MMP9, mRNA were upregulated in
SScHDF by the addition of BAFF in the coculture
(Figure 3C).
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in collagen and profibrotic markers expression
We then evaluated whether the increased collagen secre-
tion induced by B cells is due to soluble or cell-membrane
factors. B cell-induced collagen production by SScHDF was
completely inhibited by the use of transwells (Figure 3A,B).
In addition, transwells completely abrogated the effect
of B cells on α-SMA, TIMP-1, and MMP9 expression
in SScHDF (Figure 3C). Conversely, in the presence
of anti-IgM and BAFF, collagen production, as well as
α-SMA, TIMP-1, and MMP9 expression, were only par-
tially inhibited by transwells (Figure 3A,B,C).
Collectively, these data indicate that B cell-induced
collagen secretion by SScHDF is contact dependent, but
the effect of BAFF in coculture is, at least partly, dependent
on soluble factors.SScHDF Contact Transwell B cells
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CInvolvement of profibrotic cytokines in B cell- and
BAFF-induced fibrosis
To investigate the role of soluble factors in the coculture
of SScHDF with B cells, we evaluated the levels of IL-6,
CCL2, TGF-β1, and IL-1β, cytokines and chemokines
that have been shown to contribute to fibrosis. IL-1β
was not detected in any condition (data not shown).
IL-6 and CCL2 secretion were significantly increased in
coculture, and BAFF and anti-IgM enhanced their re-
lease (Figure 4A,B). Consistent with these results, inhi-
bition of cell-cell contact by using a transwell abolished
IL-6 and CCL2 induction (Figure 4A,B). Active TGF-β1
was not detected in the supernatants of cocultures with
or without BAFF. BAFF did not induce the expression of
latent TGF-β1 by fibroblasts or B cells cultured alone.
Latent TGF-β1 was upregulated by B cells, but BAFF did
not increase TGF-β1 secretion (Figure 4C). Interestingly,
contact inhibition by transwell did not completely abo-
lish the effect of BAFF stimulation on IL-6 and CCL2
secretion (Figure 4A,B,C). These findings suggest that
these cytokines might contribute to the effect of BAFF
on fibrosis.Medium
-chain Ab
 + rhBAFF
Figure 4 Profibrotic cytokines and chemokines are upregulated
in cocultures. (A-C) Levels of IL-6 (A), CCL2 (or MCP-1) (B), and latent
TGF-β1 (C) were determined by ELISA in the culture supernatants after
incubation with medium (white bars), anti-μ-chain antibodies at
5 μg/ml (grey bars), or anti-μ and rhBAFF at 100 ng/ml (black bars) in
the presence or absence of blood B cells for 3 days. B cells were either
in contact with SScHDF (contact) or seeded in the upper chamber of a
transwell culture insert (transwell). Data are expressed as the median of
duplicate samples of six independent experiments ± interquartile
range. * < 0.05; **P < 0.01; #P < 0.05 for transwell compared
with contact.B cell- and BAFF-induced fibrosis is mediated by TGF-β1
To investigate further the role of soluble factors in B
cell- and BAFF-induced collagen release by SScHDF, we
used blocking antibodies against the soluble factors that
were upregulated in cocultures, IL-6 and TGF-β1. Anti-
IL-6 antibodies only slightly reduced the release of colla-
gen by SScHDF in both contact and transwell conditions
after 5 days of culture (Figure 5B). Interestingly, blocking
TGF-β1 completely abrogated the effect of B cells and
BAFF on collagen release by SScHDF, both in contact
and transwell conditions (Figure 5A,B).
These data indicate that TGF-β1 plays a pivotal role in
the promotion of fibrosis induced by B cells and BAFF.
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Figure 5 TGF-β1 is essential for BAFF and B cell-induced collagen upregulation. (A,B) Collagen release by SScHDF was determined by
the Sircol collagen dye-binding assay in 3-day (A) and 5-day (B) culture supernatants after incubation with anti-μ at 5 μg/ml and rhBAFF
at 100 ng/ml in all conditions, and isotype control antibody at 20 μg/ml (white bars), anti-TGF-β1 antibodies at 0.2 μg/ml (dark grey bars),
anti-TGF-β1 antibodies at 1 μg/ml (light grey bars), or anti-IL-6 antibodies at 20 μg/ml (black bars). Data are expressed as the median of
duplicate samples of three independent experiments ± interquartile range. *P < 0.05.
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In this study, we demonstrated that B cells coculti-
vated with human dermal fibroblasts (HDFs) are potent
inducers of collagen and profibrotic cytokine production.
As fibrosis results from excessive collagen production
by fibroblasts, these data support the hypothesis that
B cells could play a role in the development of skin
fibrosis in SSc. So far, studies on the role of B cells
in SSc focused on their ability to secrete autoantibodies,
such as anti-DNA topoisomerase I antibodies that may
play a pathogenic role. Hénault et al. [19] showed
that binding of DNA topoisomerase I to HDF mem-
brane induces monocytes adhesion, in turn activated
by anti-topoisomerase I autoantibodies isolated from
SSc patients.
Moreover, it is well established that SSc patients show
several B-cell abnormalities, such as an overexpression
of CD19 as well as a disturbed peripheral homeostasis
[20]. SSc patients also show an expansion of naïve B
cells and reduced memory B cells and plasmablasts/early
plasma cells [21,22]. We investigated the direct inter-
action between B cells and dermal fibroblasts. First, we
demonstrated that B cells increased collagen secretion
by dermal fibroblasts with a magnitude comparable to
the stimulation of fibroblasts with recombinant TGF-β1.
Conversely, PBMCs did not induce collagen secretion,
which might be due to the opposite effect of T lympho-
cytes. It was reported that T lymphocytes inhibit collagen
secretion by dermal fibroblasts via membrane-bound
TNF-α [23,24]. Interestingly, no difference in terms of col-
lagen secretion was observed between fibroblasts ofpatients with SSc and healthy individuals. This capa-
city to increase collagen secretion might also be fur-
ther enhanced in vivo by specific properties of B cells
and the local environment observed in the disease.
Given that B cells are activated in SSc, it is also pos-
sible that SSc B cells could be more-potent inducers
of collagen production than normal B cells. This hy-
pothesis could not be tested because the effect of normal
B cells on fibroblasts is already so profound that it would
be difficult to observe any differences between SSc B cells
and normal B cells.
Coculture of B cells with SScHDF induced the secretion
of IL-6, CCL2 and TGF-β1, cytokines that are known to
stimulate the production of collagen by fibroblasts. Con-
cerning IL-6, our data are consistent with previous obser-
vations showing that coculture of a B cell line established
from lung tissue of a patient with progressive SSc and nor-
mal lung fibroblasts results in the production of high
amounts of IL-6 [25]. CCL2 is a potent inflammatory me-
diator and regulates collagen synthesis, and TGF-β1 is one
of the major cytokines implicated in SSc by regulating
extracellular matrix (ECM) production, fibroblast prolifer-
ation, and differentiation [26].
We also observed that coculture of B cells with
SScHDF promotes the expression of TIMP1 and MMP9,
which are implicated in the remodeling of the ECM.
TIMP1 and MMP9 are upregulated in the serum of SSc
patients and were found to correlate with disease activity
[18,27]. SScHDF cocultured with B cells also expressed
higher levels of α-SMA, which is a marker of differen-
tiation of fibroblasts into contractile myofibroblasts.
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http://arthritis-research.com/content/15/5/R168Myofibroblasts are specialized fibroblasts that show fea-
tures of smooth muscle cell differentiation. They also
synthesize collagen and are a major source of TGF-β1 and
TIMP-1 during the fibrotic process [28,29].
Because BAFF is a pivotal cytokine for B-cell activation
and its serum level is increased in SSc patients and cor-
relates with the extent of skin fibrosis, we subsequently
assessed whether BAFF could amplify B cell-induced fi-
brosis. First, we showed that BAFF was not secreted by
dermal fibroblasts, B cells, or in cocultures. We then
added BAFF and anti-IgM antibodies, because in vitro
stimulation of B cells with BAFF requires their activation
with anti-IgM antibodies [17]. BAFF exacerbated the effect
of B cells on collagen production by SScHDF. BAFF also
acted as a potent inducer of TIMP-1, α-SMA, CCL2, and
IL-6. A similar induction of IL-6 by BAFF was also re-
cently reported in monocytes of patients with primary
Sjögren syndrome [30].
With transwell experiments, we also showed that cyto-
kine release and collagen production are inhibited in the
absence of cell-cell contact, indicating that the effect of B
cells on SScHDF is related to membrane-bound factor(s).
Recently, the interaction α4β1 integrin/VCAM-1 (vascular
cell adhesion molecule 1) was identified as responsible for
the interaction of blood B cells with skin fibroblasts [31].
By using blocking antibodies against integrin α4/VLA-4/
CD49d, we determined that these molecules were not
implicated in B cell-induced fibrosis in this model (data
not shown). However, blocking TGF-β1 inhibited the ef-
fect of BAFF on collagen overproduction, suggesting that
TGF-β1 is the key final mediator involved in B cell-
induced fibrosis.
This suggests two hypotheses: (a) membrane TGF-β1
is directly implicated in the collaboration between B
cells and fibroblasts; and (b) an as yet unknown cell-
surface molecule on B cells (adhesion molecule, cyto-
kine) induces TGF-β1 secretion by dermal fibroblasts.
These results reinforce the rationale for targeting B
cells and/or BAFF in SSc. Recent open studies on limited
populations of patients with SSc reported that B-cell de-
pletion could result in decreased skin thickening [32-34].
This study suggests that BAFF could be an interesting
therapeutic target in SSc, by its amplifying effect on pro-
fibrotic cytokines and collagen secretion. Interestingly,
in the tight-skin mouse model, B-cell depletion or BAFF
inhibition prevents skin fibrosis [35,36].Conclusion
B cells and BAFF play a pathogenic role in skin fibrosis in
SSc by upregulating collagen secretion by dermal fibro-
blasts in a TGF-β1-dependent manner. Thus, these results
demonstrate a new pathogenic role of B cells and BAFF in
fibrosis and systemic sclerosis.Additional file
Additional file 1: Figure S1. Fibroblasts increase B-cell survival in vitro.
B cells alone or cocultured with fibroblasts were seeded in 24-well plates
for 3 or 5 days. For transwell experiments, B cells (5 × 105 cells) and HDF
(105 cells) were seeded in the upper and lower chambers, respectively.
After 3 or 5 days, B-cell viability was determined by FACS analysis; vital B
cells were brightly positive when stained with DiOC6 and excluded PI.
Data are expressed as the median of duplicate samples of two
independent experiments ± interquartile range.
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